Search

Your search keyword '"Guerrini-Rousseau, Lea"' showing total 12 results
Start Over Author "Guerrini-Rousseau, Lea" Search Limiters Peer Reviewed
12 results on '"Guerrini-Rousseau, Lea"'

1. The role of cancer predisposition syndrome in children and adolescents with very rare tumours

Author

Orbach, Daniel, Brecht, Ines B., Corradini, Nadege, Bouchoucha, Yassine, Roganovic, Jelena, Bourdeaut, Franck, Reguerre, Yves, Kuiper, Roland P., Bressac de Paillerets, Brigitte, Ferrari, Andrea, Virgone, Calogero, Godzinski, Jan, Bisogno, Gianni, Guerrini-Rousseau, Lea, Farinha, Nuno Jorge, Bergamaschi, Luca, Bien, Ewa, Kuhlen, Michaela, Schneider, Dominik T., and Ben Ami, Tal

Published
2023
Full Text
View/download PDF

2. Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair Deficiency

Author

Gallon, Richard, Phelps, Rachel, Hayes, Christine, Brugieres, Laurence, Guerrini-Rousseau, Léa, Colas, Chrystelle, Muleris, Martine, Ryan, Neil A.J., Evans, D. Gareth, Grice, Hannah, Jessop, Emily, Kunzemann-Martinez, Annabel, Marshall, Lilla, Schamschula, Esther, Oberhuber, Klaus, Azizi, Amedeo A., Baris Feldman, Hagit, Beilken, Andreas, Brauer, Nina, Brozou, Triantafyllia, Dahan, Karin, Demirsoy, Ugur, Florkin, Benoît, Foulkes, William, Januszkiewicz-Lewandowska, Danuta, Jones, Kristi J., Kratz, Christian P., Lobitz, Stephan, Meade, Julia, Nathrath, Michaela, Pander, Hans-Jürgen, Perne, Claudia, Ragab, Iman, Ripperger, Tim, Rosenbaum, Thorsten, Rueda, Daniel, Sarosiek, Tomasz, Sehested, Astrid, Spier, Isabel, Suerink, Manon, Zimmermann, Stefanie-Yvonne, Zschocke, Johannes, Borthwick, Gillian M., Wimmer, Katharina, Burn, John, Jackson, Michael S., and Santibanez-Koref, Mauro

Published
2023
Full Text
View/download PDF

3. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma

Author

Benusiglio, Patrick R., Elder, Fikret, Touat, Mehdi, Perrier, Alexandre, Sanson, Marc, Colas, Chrystelle, Guerrini-Rousseau, Lea, Tran, Duy Thanh, Trabelsi, Nesrine, Carpentier, Catherine, Marie, Yannick, Adam, Clovis, Bernier, Michèle, Cazals-Hatem, Dominique, Mokhtari, Karima, Tran, Suzanne, Mathon, Bertrand, Capelle, Laurent, Dhooge, Marion, Idbaih, Ahmed, Alentorn, Agusti, Houillier, Caroline, Dehais, Caroline, Hoang-Xuan, Khe, Cuzzubbo, Stefania, Carpentier, Antoine, Duval, Alex, Coulet, Florence, and Bielle, Franck

Published
2023
Full Text
View/download PDF

7. Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome.

Author

Kolodziejczak, Anna S, Guerrini-Rousseau, Lea, Planchon, Julien Masliah, Ecker, Jonas, Selt, Florian, Mynarek, Martin, Obrecht, Denise, Sill, Martin, Autry, Robert J, Stutheit-Zhao, Eric, Hirsch, Steffen, Amouyal, Elsa, Dufour, Christelle, Ayrault, Olivier, Torrejon, Jacob, Waszak, Sebastian M, Ramaswamy, Vijay, Pentikainen, Virve, Demir, Haci Ahmet, and Clifford, Steven C

Published
2023
Full Text
View/download PDF

10. Germline Mutations Predispose to Pediatric Medulloblastoma.

Author

Begemann, Matthias, Waszak, Sebastian M., Robinson, Giles W., Jäger, Natalie, Sharma, Tanvi, Knopp, Cordula, Kraft, Florian, Moser, Olga, Mynarek, Martin, Guerrini-Rousseau, Lea, Brugieres, Laurence, Varlet, Pascale, Pietsch, Torsten, Bowers, Daniel C., Chintagumpala, Murali, Sahm, Felix, Korbel, Jan O., Rutkowski, Stefan, Eggermann, Thomas, and Gajjar, Amar

Published
2020
Full Text
View/download PDF

11. Mesenchymal Transition and PDGFRA Amplification/ Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas.

Author

Puget, Stephanie, Philippe, Cathy, Bax, Dorine A., Job, Bastien, Varlet, Pascale, Junier, Marie-Pierre, Andreiuolo, Felipe, Carvalho, Dina, Reis, Ricardo, Guerrini-Rousseau, Lea, Roujeau, Thomas, Dessen, Philippe, Richon, Catherine, Lazar, Vladimir, Teuff, Gwenael Le, Sainte-Rose, Christian, Geoerger, Birgit, Vassal, Gilles, Jones, Chris, and Grill, Jacques

Subjects
BRAIN cancer, MESENCHYMAL stem cells, GENE expression, RADIOTHERAPY, BIOPSY
Abstract

Diffuse intrinsic pontine glioma (DIPG) is one of the most frequent malignant pediatric brain tumor and its prognosis is universaly fatal. No significant improvement has been made in last thirty years over the standard treatment with radiotherapy. To address the paucity of understanding of DIPGs, we have carried out integrated molecular profiling of a large series of samples obtained with stereotactic biopsy at diagnosis. While chromosomal imbalances did not distinguish DIPG and supratentorial tumors on CGHarrays, gene expression profiling revealed clear differences between them, with brainstem gliomas resembling midline/thalamic tumours, indicating a closely-related origin. Two distinct subgroups of DIPG were identified. The first subgroup displayed mesenchymal and pro-angiogenic characteristics, with stem cell markers enrichment consistent with the possibility to grow tumor stem cells from these biopsies. The other subgroup displayed oligodendroglial features, and appeared largely driven by PDGFRA, in particular through amplification and/or novel missense mutations in the extracellular domain. Patients in this later group had a significantly worse outcome with an hazard ratio for early deaths, ie before 10 months, 8 fold greater that the ones in the other subgroup (p = 0.041, Cox regression model). The worse outcome of patients with the oligodendroglial type of tumors was confirmed on a series of 55 paraffin-embedded biopsy samples at diagnosis (median OS of 7.73 versus 12.37 months, p = 0.045, log-rank test). Two distinct transcriptional subclasses of DIPG with specific genomic alterations can be defined at diagnosis by oligodendroglial differentiation or mesenchymal transition, respectively. Classifying these tumors by signal transduction pathway activation and by mutation in pathway member genes may be particularily valuable for the development of targeted therapies [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

12. Relapsing intracranial germ cell tumours warrant retreatment.

Author

Callec, Laetitia, Lardy-Cleaud, Audrey, Guerrini-Rousseau, Lea, Alapetite, Claire, Vignon, Laure, Chastagner, Pascal, Frappaz, Didier, and Faure-Conter, Cecile

Subjects
*ANTINEOPLASTIC agents, *BRAIN tumors, *ADJUVANT treatment of cancer, *CANCER chemotherapy, *CANCER relapse, *CONFIDENCE intervals, *DOSE-effect relationship in pharmacology, *MEDICAL records, *SURVIVAL, *TREATMENT effectiveness, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *GERMINOMA, *ACQUISITION of data methodology, *CHEMORADIOTHERAPY
Abstract

The optimal therapeutic strategy for relapsing intracranial germ cell tumours (IGCTs) has not been clearly established. Relapses of IGCTs, occurring from 01/01/1990 to 31/12/2014, were retrieved from the Societe Française d'Oncologie Pediatrique-TGM 90, 92 and GCT 96 protocols, and from the National Childhood Solid Tumour Registry. Refractory IGCTs were excluded. Forty-four relapsing IGCTs were identified: 14 were initially treated for histologically proven germinomas (germinoma group), 5 for non-histologically proven germinomas (putative germinoma group) and 25 for non-germinomatous germ cell tumours (NGGCTs) (NGGCT group). In the germinoma group, the 5-year event-free survival (EFS) and overall survival (OS) were 79% (95% confidence interval [CI]: 47–93) and 86% (95% CI: 54–96), respectively. Only one of the 11 patients treated with reirradiation experienced a further relapse. A trend of better EFS was observed for relapses at sites that were not initially involved: 5-year EFS of 100% versus 67% (95% CI: 28–88), p = 0.09. In the putative germinoma group, 4 of 5 patients experienced a further event, leading to 2 deaths. In the NGGCT group, the 5-year EFS and OS were 56% (95% CI: 35–73) and 60% (95% CI: 38–76), respectively. A significant improvement in outcomes after high-dose chemotherapy (HDC) was observed: 5-year OS of 72% (95% CI: 46–87) versus 29% (95% CI: 4–61), p = 0.006. Relapsing germinomas are highly curable; reirradiation appears to play a key role. Histological proof at initial diagnosis if markers are negative is crucial. Despite inferior outcomes relapsing, NGGCTs can be cured in a significant proportion of cases provided intensive treatment including HDC is applied. • Histology at diagnosis and at relapse has an impact on prognosis. • Relapsing germinomas are highly curable; reirradiation appears to play a key role. • In this group, high-dose chemotherapy (HDC) with reirradiation may be overtreatment. • Recurrent non-germinomatous germ cell tumours have a less favourable prognosis. • In this group, both HDC and reirradiation are required for cure. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results